Strategic Signals Weekly: March 15 – March 22, 2026
March 22, 2026
Genprex, Inc. strategic review ongoing (Reqorsa Gene Therapy (quaratusugene ozeplasmid)). 14 signals this week: 1 strategic, 11 financing.
Independent Biotech Intelligence
Primary source data for business development, investors, and strategy teams. Trials, filings, patents, and markets - linked and traceable.
About RxDataLab
Research and data tools for the business of biotech
RxDataLab tracks clinical programs, regulatory filings, and market activity for the biotech industry. We build tools for business development teams, investors, and strategy groups who need reliable primary source data. We also publish original analysis from the same data.
Learn more →What's in the Platform
Primary-source data on the business of biotech. Clinical trials, regulatory filings, biotech hedge fund positioning, and insider trading. Updated daily.
Clinical Trial Tracker
Pipeline changes, trial status updates, and competitive landscape mapping across 450K+ trials.
BioHedge
Hedge fund positioning in biotech stocks, updated daily based on schedule 13 filings.
Strategic Signals
Deal activity, partnership filings, and business development signals directly from SEC filings.
Insider Activity
Executive and director trades filed with the SEC, linked to company pipelines.
Financial Context
10-Q Disclosures — select overlays to view events in context
Financial history for
Xenon Pharmaceuticals Inc.
(XENE)
— RxDataLab Platform
Overlay:
|
|
Cash
R&D
G&A
◆ = annual (10-K)
Events in View
Want to explore more companies? We cover 500+ — filings, trials, insider trades, and institutional moves, all in one view.
Signup →Research & Resources
Recent Analysis
View all →BioHedge Weekly: March 15 – March 22, 2026
March 22, 2026
Perceptive Advisors initiated new 5.3% position in Relay Therapeutics, Inc.. 4 filings this week, 3 activist, 1 passive.
SEC Ownership Filings in Biotech and What We Can Learn From Them
February 20, 2026
How to read SEC beneficial ownership and insider reporting filings such as Schedule 13D, 13G, Form 13F, and Form 4 and what they reveal when you layer them together for biotech companies.
RxDataLab Research Notes
Primary-source analysis of biotech companies: clinical trials, SEC filings, and hedge fund positioning. Get notified when we publish. No fixed schedule, no filler.
Traceable data for BD, investors, and strategy teams
RxDataLab links regulatory filings to clinical programs and markets, giving you the full picture of who’s filing, what trials they’re running, and how everything connects. Clinical trial records, SEC filings, patent data, and market feeds from primary sources. Every data point traces back to the original filing.
Or email directly at
[email protected]